Prostate cancer is the most common cancer among men in developed countries. Hormonal agents are the mainstay of treatment for prostate cancer and are routinely used throughout the course of disease progression. Zytiga [Johnson & Johnson/Janssen Biotech/Janssen-Cilag/AstraZeneca’s abiraterone] and Xtandi [Pfizer/Astellas’s enzalutamide]) are cornerstone treatments for mCRPC, and several clinical trials are evaluating their role in earlier stages of the disease. Several therapies are also being positioned for the untapped and potentially lucrative nonmetastatic CRPC setting. The late-phase pipeline for mCRPC has also become more dynamic with three PARP inhibitors (AstraZeneca’s Lynparza [olaparib], Clovis Oncology’s Rubraca [rucaparib] and Pfizer’s talazoparib) and one immune checkpoint inhibitor (Roche/Genentech/Chugai’s Tecentriq [atezolizumab]) entering Phase III development.
Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.